Scientific EXPERT Act of 2025
Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a process for science-focused drug development meetings led by the Reagan-Udall Foundatio… Show full official titleShow less
Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a process for science-focused drug development meetings led by the Reagan-Udall Foundation for the Food and Drug Administration with respect to drugs for rare diseases and conditions, and for other purposes.
More subjectsShow fewer subjects
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Scientific External Process for Educated Review of Therapeutics Act of 2025 or the Scientific EXPERT Act of 2025
This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions.
The FDA must enter into an arrangement with the Reagan-Udall Foundation for the FDA under which the foundation agrees to convene such meetings. Meetings must be held at least four times a year, and each meeting must focus on a different rare disease or condition.
The foundation must establish a permanent steering committee to review and recommend topics for each meeting. In evaluating potential topics, the committee must consider unmet therapeutic needs, patient population sizes for different diseases and conditions, and whether a disease or condition would benefit from clarity and alignment on drug development questions, among other factors.
In planning each meeting, the foundation must develop a list of medical experts, drug sponsors, scientific organizations, patient organizations, and other entities to be invited to participate. Representatives of the FDA’s review divisions must attend each meeting.
After each meeting, the foundation must make available a summary of the meeting noting areas of consensus, areas where additional clarification or information is needed, and next steps agreed upon with the FDA.
The bill also requires the FDA to indicate whether it incorporated any input from these meetings when approving a new drug or biologic.
- Introduced in Senate Formatted Text PDF Formatted XML
- BIOTECHNOLOGY INNOVATION ORGANIZATION
- PTC THERAPEUTICS, INC.
- BRIDGEBIO PHARMA, INC.
- RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
- RARE DISEASE COMPANY COALITION
- BIOTECHNOLOGY INNOVATION ORGANIZATION
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Commerce, Dept of (DOC)
- Health & Human Services, Dept of (HHS)
- Natl Security Council (NSC)
- Office of Management & Budget (OMB)
- Patent & Trademark Office (PTO)
- Treasury, Dept of
Cite this page
U.S. Congress. (2026). S. 822: Scientific EXPERT Act of 2025. 119th Congress. Open America. https://openamerica.io/bill/119-S-822/
"S. 822: Scientific EXPERT Act of 2025." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-822/.
S. 822, 119th Cong. (2026), https://openamerica.io/bill/119-S-822/.
[S. 822: Scientific EXPERT Act of 2025](https://openamerica.io/bill/119-S-822/)